Lipid-loaded microglia, also known as foam cells, are a specialized subset of microglia that have accumulated large amounts of intracellular lipid droplets. These cells represent a distinct activation state characterized by metabolic reprogramming and are increasingly recognized as important players in neurodegenerative diseases, particularly Alzheimer's disease (AD)[1]. Foam cells in the brain share morphological and functional similarities with atherosclerotic foam cells, representing a final common pathway for lipid handling in chronic inflammatory conditions[2].
The term "foam cell" derives from the vacuolated, foamy appearance these cells exhibit under microscopy due to accumulated lipid droplets. In the brain, lipid-loaded microglia arise from chronic exposure to amyloid-beta, APOE4-associated lipid dysregulation, and ongoing neuroinflammation[3]. These cells are now recognized as a key therapeutic target, particularly through the TREM2-APOE pathway.
| Property | Value |
|---|---|
| Lineage | Glia > Microglia > Lipid-Loaded |
| Markers | TREM2, APOE, PLIN2, CD68, LPL, ABCA1 |
| Brain Regions | Cortex, Hippocampus, White Matter, Perivascular Regions |
| Disease Association | Alzheimer's Disease, Atherosclerosis, Multiple Sclerosis, Parkinson's Disease |
Lipid-loaded microglia derive from resident microglia through a process of lipid accumulation:
Lipid-loaded microglia represent a specific activation state within the disease-associated microglia (DAM) continuum:
Lipid-loaded microglia exhibit distinctive morphological features:
| Marker | Function | Significance |
|---|---|---|
| TREM2 | Triggering receptor on myeloid cells 2 | Critical for lipid clearance, AD risk gene |
| APOE | Apolipoprotein E | Primary lipid carrier in brain, AD risk gene |
| PLIN2 | Perilipin 2 | Lipid droplet coating protein |
| CD68 | Cluster of differentiation 68 | Phagocytic marker, lysosomal protein |
| LPL | Lipoprotein lipase | Hydrolyzes triglycerides |
| ABCA1 | ATP-binding cassette transporter A1 | Cholesterol efflux regulator |
Under normal conditions, microglia participate in brain lipid homeostasis:
In the healthy brain, lipid-handling microglia:
Lipid-loaded microglia are central to AD pathogenesis through multiple mechanisms:
The TREM2-APOE axis critically regulates foam cell formation:
| TREM2 Variant | Effect | Clinical Consequence |
|---|---|---|
| R47H | 3-4x AD risk | Impaired lipid clearance |
| R62H | Moderate risk | Reduced TREM2 function |
| TREM2 knockout | Complete loss | No foam cell formation |
Foam cells accumulate lipids through multiple receptors:
The key defect in foam cell formation:
| Normal Pathway | Foam Cell Defect |
|---|---|
| ABCA1 → APOE → HDL | Impaired ABCA1 function |
| ABCG1 → Cholesterol → HDL | Reduced ABCG1 expression |
| Result: Balance | Result: Lipid accumulation |
Cholesterol crystals and lipid droplets activate NLRP3:
| Target | Strategy | Status |
|---|---|---|
| TREM2 | Agonistic antibodies | Clinical trials (NCT04592874) |
| ABCA1 | Agonists to enhance cholesterol efflux | Preclinical |
| NLRP3 | Inflammasome inhibitors | Phase 2 trials |
| APOE | Gene therapy to increase APOE expression | Research stage |
Lipid-loaded microglial markers in CSF and blood:
The study of Lipid Loaded Microglia (Foam Cells) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Keren-Shaul H, Spinrad A, Weiner A, et al. A Unique Microglia Type Associated with Alzheimer's Disease. Cell. 2017;169(7):1276-1290.e17. https://doi.org/10.1016/j.cell.2017.05.018 ↩︎
Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell. 2010;140(6):918-934. https://doi.org/10.1016/j.cell.2010.02.016 ↩︎
Ulrich JD, Holtzman DM. TREM2 Function in Alzheimer's Disease and Neurodegeneration. ACS Chemical Neuroscience. 2016;7(4):420-427. https://doi.org/10.1021/acschemneuro.6b00026 ↩︎
Braak H, Thal DR, Ghebremedhin E, Del Tredici K. Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. Journal of Neuropathology & Experimental Neurology. 2011;70(11):960-969. https://doi.org/10.1097/NEN.0b013e318232a379 ↩︎